Announcements Trials
Browse Landscape

Phase

Phase 2 153Phase 1 32Phase 1/2 29Phase 3 20Phase NA 5Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 3

Status

Completed 7Withdrawn 3Terminated 3Active not recruiting 3Unknown 2Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Brain Neoplasms 2von Hippel-Lindau Disease 1Hemangioblastoma 1Gliosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Bevacizumab × Clear all
NCT04074785 2025-08-17

SCCC-06319

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT01086345 2018-07-03

Radiosurgery Plus Bevacizumab in Glioblastoma

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
9 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Terminated
1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡